Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Patients with irritable bowel syndrome (IBS) experience abdominal pain, altered bowel habits, and defecation-related anxiety, which can result in reduced productivity and impaired health-related quality of life (HRQL). Cognitive behavioral therapy (CBT) has been shown to reduce symptoms of IBS and to improve HRQL, but access to qualified therapists is limited. Smartphone-based digital therapeutic interventions have potential to increase access to guided CBT at scale, but require careful study to assess their benefits and risks. Objective: The aim of this study was to test the efficacy of a novel app, Zemedy, as a mobile digital therapeutic that delivers a comprehensive CBT program to individuals with IBS. Methods: This was a crossover randomized controlled trial. Participants were recruited online and randomly allocated to either immediate treatment (n=62) or waitlist control (n=59) groups. The Zemedy app consists of 8 modules focusing on psychoeducation, relaxation training, exercise, the cognitive model of stress management, applying CBT to IBS symptoms, reducing avoidance through exposure therapy, behavioral experiments, and information about diet. Users interact with a chatbot that presents the information and encourages specific plans, homework, and exercises. The treatment was fully automated, with no therapist involvement or communication. At baseline and after 8 weeks, participants were asked to complete the battery of primary (Irritable Bowel Syndrome Quality of Life [IBS-QOL], Gastrointestinal Symptom Rating Scale [GSRS]) and secondary (Fear of Food Questionnaire [FFQ], Visceral Sensitivity Index [VSI], Gastrointestinal Cognition Questionnaire [GI-COG], Depression Anxiety Stress Scale [DASS], and Patient Health Questionnaire-9 [PHQ-9]) outcome measures. Waitlist controls were then offered the opportunity to crossover to treatment. All participants were assessed once more at 3 months posttreatment. Results: Both intention-to-treat and completer analyses at posttreatment revealed significant improvement for the immediate treatment group compared to the waitlist control group on both primary and secondary outcome measures. Gains were generally maintained at 3 months posttreatment. Scores on the GSRS, IBS-QoL, GI-COG, VSI, and FFQ all improved significantly more in the treatment group (F1,79=20.49, P<.001, Cohen d=1.01; F1,79=20.12, P<.001, d=1.25; F1,79=34.71, P<.001, d=1.47; F1,79=18.7, P<.001, d=1.07; and F1,79=12.13, P=.001, d=0.62, respectively). Depression improved significantly as measured by the PHQ-9 (F1,79=10.5, P=.002, d=1.07), and the DASS Depression (F1,79=6.03, P=.02, d=.83) and Stress (F1,79=4.47, P=.04, d=0.65) subscales in the completer analysis but not in the intention-to-treat analysis. The impact of treatment on HRQL was mediated by reductions in catastrophizing and visceral sensitivity. Conclusions: Despite its relatively benign physical profile, IBS can be an extraordinarily debilitating condition. Zemedy is an effective modality to deliver CBT for individuals with IBS, and could increase accessibility of this evidence-based treatment. Trial Registration: ClinicalTrials.gov NCT04170686; https://www.clinicaltrials.gov/ct2/show/NCT04170686
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Jacobson, N. S., & Truax, P. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.12 · Cited by 7,770
Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples
Brown, T. A., Chorpita, B. F., Korotitsch, W., & Barlow, D. H. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(96)00068-x · Cited by 1,860
Crawford, J. R., & Henry, J. D. (2003) · British Journal of Clinical Psychology · doi:10.1348/014466503321903544 · Cited by 1,756 · cited 1×
“The DASS has been found to be a highly reliable and valid measure of the constructs it is intended to assess [42].”
BackgroundDevelopment and validation of the user version of the Mobile application rating scale (uMARS)
Stoyanov, S. R., Hides, L., Kavanagh, D. J., & Wilson, H. (2016) · JMIR mhealth and uhealth · doi:10.2196/mhealth.5849 · Cited by 872
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 1×
“The IBS-Quality of Life (IBS-QOL) questionnaire is a 34-item self-report measure specific to IBS designed to assess the impact of IBS on quality of life [31,32].”
BackgroundLabus, J. S., Bolus, R., Chang, L., Wiklund, I., Naesdal, J., Mayer, E. A., & Naliboff, B. D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02007.x · Cited by 475 · cited 1×
“The Visceral Sensitivity Index (VSI) is a unidimensional 15-item scale that measures GI symptom–specific anxiety [6,37].”
BackgroundFurther validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424
An irritable bowel syndrome-specific symptom questionnaire: development and validation
K., W. I., S., F., J., H. C., H., J. R., F., L. G., A., M. E., A., P. R., K., W. I., & J., N. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310004209 · Cited by 324
Cited by
Roles, Users, Benefits, and Limitations of Chatbots in Health Care: Rapid Review
Laymouna, M., Ma, Y., Lessard, D., Schuster, T., Engler, K., & Lebouché, B. (2024) · Journal of Medical Internet Research · doi:10.2196/56930 · Cited by 305
Roles, Users, Benefits, and Limitations of Chatbots in Health Care: Rapid Review (Preprint)
Laymouna, M., Ma, Y., Lessard, D., Schuster, T., Engler, K., & Lebouché, B. (2024) · doi:10.2196/preprints.56930 · Cited by 302
He, Y., Yang, L., Qian, C., Li, T., Su, Z., Zhang, Q., & Hou, X. (2023) · Journal of Medical Internet Research · doi:10.2196/43862 · Cited by 213
Zhong, W., Luo, J., & Zhang, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.057 · Cited by 173
Jabir, A. I., Martinengo, L., Lin, X., Torous, J., Subramaniam, M., & Tudor Car, L. (2023) · Journal of Medical Internet Research · doi:10.2196/44548 · Cited by 63
“[4,13,29,34-37], or a laptop/desktop-based program (7/32, 17”
InfluentialFeng, X., Tian, L., Ho, G. W. K., Yorke, J., & Hui, V. (2025) · Journal of Medical Internet Research · doi:10.2196/79850 · Cited by 51
Johnson, E., Corrick, S., Isley, S., Vandermeer, B., Dolgoy, N., Bates, J., Godfrey, E., Soltys, C., Muir, C., Vohra, S., et al. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000435 · Cited by 24
“Eighteen of the studies included in this review reported on adverse events, including reporting zero events (n = 9) [52, 54, 55, 59, 61, 76, 83, 84, 87].”
BackgroundUsability and feasibility of a cognitive-behavioral mobile app for ADHD in adults
Knouse, L. E., Hu, X., Sachs, G., & Isaacs, S. (2022) · PLOS Digital Health · doi:10.1371/journal.pdig.0000083 · Cited by 18
Metadata
- Authors
- Hunt, M., Miguez, S., Dukas, B., Onwude, O., & White, S.
- Venue
- JMIR mHealth and uHealth
- Publisher
- JMIR Publications Inc.
- Published
- 2021-05-20
- Volume
- 9
- Issue
- 5
- Pages
- e26152
- ISSN
- 2291-5222 (ISSN-L)
- OpenAlex
- W3156818268
- Cited by
- 98
- References
- 29
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.